Ana Drozdowskyj

7.6k total citations
31 papers, 1.0k citations indexed

About

Ana Drozdowskyj is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ana Drozdowskyj has authored 31 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Ana Drozdowskyj's work include Lung Cancer Treatments and Mutations (20 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Ana Drozdowskyj is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Ana Drozdowskyj collaborates with scholars based in Spain, United States and Italy. Ana Drozdowskyj's co-authors include Niki Karachaliou, Rafael Rosell, Ana Giménez‐Capitán, Santiago Viteri, Miguel Ángel Molina‐Vila, Cristina Teixidó, Trever G. Bivona, Jordi Bertrán-Alamillo, Jordi Berenguer and María González‐Cao and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ana Drozdowskyj

31 papers receiving 990 citations

Peers

Countries citing papers authored by Ana Drozdowskyj

Since Specialization

Citations

This map shows the geographic impact of Ana Drozdowskyj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Drozdowskyj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Drozdowskyj more than expected).

Fields of papers citing papers by Ana Drozdowskyj

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Drozdowskyj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Drozdowskyj. The network helps show where Ana Drozdowskyj may publish in the future.

Co-authorship network of co-authors of Ana Drozdowskyj

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Drozdowskyj. A scholar is included among the top collaborators of Ana Drozdowskyj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Drozdowskyj. Ana Drozdowskyj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Access to melanoma drugs in Spain: a cross-sectional survey 2024 ·Clinical & Translational Oncology ·María González‐Cao, Teresa Puértolas, José Luís Zamora Manzano, (unknown), Oriol Yélamos, Miguel‐Ángel Berciano‐Guerrero, Pablo Cerezuela, Juan Martín-Liberal, Eva Muñoz‐Couselo, Enrique Espinosa, Ana Drozdowskyj, Alfonso Berrocal, Ainara Soria, Iván Márquez‐Rodas, Salvador Martín‐Algarra, María Quindós, Susana Puig, (unknown)	3
2	Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis 2024 ·Clinical & Translational Oncology ·(unknown), María González‐Cao, Teresa Puértolas, José Luís Zamora Manzano, (unknown), Oriol Yélamos, Miguel‐Ángel Berciano‐Guerrero, Juan Martín-Liberal, Eva Muñoz‐Couselo, Enrique Espinosa, Ana Drozdowskyj, Alfonso Berrocal, Ainara Soria, Iván Márquez‐Rodas, Salvador Martín‐Algarra, María Quindós, Susana Puig, (unknown)	1
3	Prospective Investigation of Nanoplastic Accumulation in Healthy Subjects, Autoimmune Diseases, Hematological Malignancies, Lung Cancer, and Murine Models 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Laura G. Rico, Ana Drozdowskyj, Michael D. Ward, (unknown), (unknown), Marta Vives‐Pi, (unknown), Jordi Pétriz	1
4	The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC 2021 ·Lung Cancer ·Delvys Rodríguez‐Abreu, Manuel Cobo, (unknown), Santiago Viteri, Núria Jordana‐Ariza, Beatriz García‐Peláez, Noemı́ Reguart, Andrés Aguilar, Jordi Codony‐Servat, Ana Drozdowskyj, (unknown), E. D'Hondt, Rafael Rosell	3
5	BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib 2020 ·JTO Clinical and Research Reports ·Niki Karachaliou, Óscar Arrieta, Ana Giménez‐Capitán, Erika Aldeguer, Ana Drozdowskyj, Imane Chaib, Noemı́ Reguart, Rosario García‐Campelo, Jinghua Chen, Miguel Ángel Molina‐Vila, Rafael Rosell	9
6	Cancer Stem Cell Biomarkers in EGFR-Mutation–Positive Non–Small-Cell Lung Cancer 2019 ·Clinical Lung Cancer ·Jordi Codony‐Servat, Carles Codony, Andrés F. Cardona, Ana Giménez‐Capitán, Ana Drozdowskyj, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Niki Karachaliou, Rafael Rosell	39
7	Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution. 2019 ·Journal of Clinical Oncology ·Jillian Wilhelmina Paulina Bracht, Niki Karachaliou, Richard B. Lanman, Daniel Dix, Iris Faull, Rebecca J. Nagy, (unknown), Ramón Palmero, Santiago Viteri, Margarita Majem, Álvaro Taus, Enric Carcereny, J. Garde, (unknown), Andrea Malfettone, (unknown), Ana Drozdowskyj, Enriqueta Felip, Rafael Rosell	1
8	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Niki Karachaliou, Jillian Wilhelmina Paulina Bracht, (unknown), Ana Drozdowskyj, Ana Giménez‐Capitán, Teresa Morán, Enric Carcereny, Manuel Cobo, Manuel Dómine, Imane Chaib, José Luis Ramírez, Carlos Camps, Mariano Provencio, A. Vergnenègre, Guillermo López-Vivanco, Margarita Majem, Bartomeu Massutí, Rafael Rosell	13
9	Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC) 2018 ·EBioMedicine ·Niki Karachaliou, Andrés F. Cardona, Jillian Wilhelmina Paulina Bracht, Erika Aldeguer, Ana Drozdowskyj, (unknown), Imane Chaib, Jordi Berenguer, Mariacarmela Santarpía, Masaoki Ito, Jordi Codony‐Servat, Rafael Rosell	35
10	AXL and CDCP1: A roadmap of innate resistance in EGFR mutant NSCLC. 2018 ·Journal of Clinical Oncology ·Niki Karachaliou, Imane Chaib, Andrés F. Cardona, Jordi Berenguer, Jillian Wilhelmina Paulina Bracht, Jie Yang, Xueting Cai, Zhigang Wang, Ana Drozdowskyj, Ilaria Attili, July Rodríguez, (unknown), Santiago Viteri, Sai‐Hong Ignatius Ou, Tony Mok, Trever G. Bivona, Mayumi Ono, Jingrong Jean Cui, Peng Cao, Rafael Rosell	1
11	Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy 2018 ·Melanoma Research ·María González‐Cao, (unknown), (unknown), José Luís Zamora Manzano, Miguel Ángel Molina‐Vila, Vincent Soriano, Teresa Puértolas, (unknown), Ainara Soria, Margarita Majem, Clara Montagut, Eva Muñoz, Delvys Rodríguez‐Abreu, (unknown), (unknown), Javier Cortés, Ana Drozdowskyj, Niki Karachaliou, Rafael Rosell	14
12	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer 2017 ·Nature Communications ·Kirstine Jacobsen, Jordi Bertrán-Alamillo, Miguel Ángel Molina‐Vila, Cristina Teixidó, Niki Karachaliou, Martin H. Pedersen, Josep Castellví, Mónica Garzón, Carles Codony, Jordi Codony‐Servat, Ana Giménez‐Capitán, Ana Drozdowskyj, Santiago Viteri, Martin R. Larsen, Ulrik Lassen, Enriqueta Felip, Trever G. Bivona, Henrik J. Ditzel, Rafael Rosell	118
13	OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer 2017 ·Journal of Thoracic Oncology ·Rafael Rosell, Imane Chaib, Niki Karachaliou, Peng Cao, (unknown), Xueting Cai, Ana Drozdowskyj, Jie Yang, Chunping Hu, Andrés F. Cardona, Alex Frías, Chiara Lazzari, Alberto Verlicchi, (unknown), Carles Codony, José Luis Ramírez, A. Vergnenègre, (unknown), Trever G. Bivona	1
14	Interferon-gamma (INFG), an important marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients. 2017 ·Journal of Clinical Oncology ·Niki Karachaliou, Guillermo Crespo, Erika Aldeguer, Ana Drozdowskyj, Ana Giménez‐Capitán, Cristina Teixidó, Miguel Ángel Molina‐Vila, Santiago Viteri, Daniela Morales-Espinosa, María de los Llanos Gil, María González‐Cao, Salvador Martín‐Algarra, Elísabeth Pérez-Ruiz, Iván Márquez‐Rodas, Delvys Rodríguez‐Abreu, Remei Blanco, Teresa Puértolas, (unknown), Rafael Rosell	12
15	BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors 2015 ·Melanoma Research ·María González‐Cao, Clara Mayo‐de‐las‐Casas, Miguel Ángel Molina‐Vila, Leticia De Mattos‐Arruda, Eva Muñoz‐Couselo, José Luís Zamora Manzano, Javier Cortés, (unknown), Ana Drozdowskyj, Miguel F. Sanmamed, Álvaro González, Carlos Álvarez-Fernández, Santiago Viteri, Niki Karachaliou, Salvador Martín‐Algarra, Jordi Bertrán-Alamillo, Núria Jordana‐Ariza, Rafael Rosell	65
16	Erlotinib-Associated Rash in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated in the EURTAC Trial 2015 ·Future Oncology ·Filippo de Marinis, A. Vergnenègre, Antonio Passaro, Catherine Dubos‐Arvis, Enric Carcereny, Ana Drozdowskyj, Ali Zeaiter, Pablo Ernesto Pérez, Rafael Rosell	8
17	EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients. 2015 ·Journal of Clinical Oncology ·Niki Karachaliou, R. Jonas A. Nilsson, Jordi Berenguer, Ana Giménez‐Capitán, Pepijn Schellen, Cristina Teixidó, Justine L. Kuiper, Esther E.E. Drees, (unknown), (unknown), Jihane Tannous, Daniëlle A.M. Heideman, Erik Thunnissen, Anne‐Marie C. Dingemans, Santiago Viteri, Bakhos A. Tannous, Ana Drozdowskyj, Egbert F. Smit, Thomas Würdinger, Rafael Rosell	3
18	The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial 2014 ·Clinical Cancer Research ·Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj, Ana Giménez‐Capitán, Jordi Bertrán-Alamillo, Niki Karachaliou, Radj Gervais, Bartomeu Massutí, Jia Wei, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García‐Campelo, Santiago Viteri, Miquel Tarón, Mayumi Ono, Petros Giannikopoulos, Trever G. Bivona, Rafael Rosell	180
19	ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation. 2014 ·PubMed ·Niki Karachaliou, Ana Giménez‐Capitán, Ana Drozdowskyj, Santiago Viteri, Teresa Morán, Enric Carcereny, Bartomeu Massutí, A. Vergnenègre, Filippo de Marinis, Miguel Ángel Molina‐Vila, Cristina Teixidó, Rafael Rosell	29
20	EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study. 2012 ·Journal of Clinical Oncology ·Rafael Rosell, Miguel Ángel Molina‐Vila, Miquel Tarón, Jordi Bertran-Alamillo, Clara Mayo, A. Vergnenègre, Filippo de Marinis, Bartomeu Massutí, Javier de Castro, Radj Gervais, Enric Carcereny, Cristina Bugés, Teresa Morán, Mariacarmela Santarpía, Enriqueta Felip, Margarita Majem, Joaquim Bosch‐Barrera, Felipe Cardenal, Ana Drozdowskyj, Trever G. Bivona	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact